Clinical Trials Logo

Myeloproliferative Disorder clinical trials

View clinical trials related to Myeloproliferative Disorder.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05884333 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Cord Blood Transplant in Adults With Blood Cancers

Start date: May 22, 2023
Phase: Phase 2
Study type: Interventional

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.

NCT ID: NCT03869476 Recruiting - Clinical trials for Essential Thrombocythemia

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.

BioScoreSMP
Start date: July 30, 2019
Phase: N/A
Study type: Interventional

Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.

NCT ID: NCT03852407 Recruiting - Multiple Myeloma Clinical Trials

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

HLA
Start date: February 4, 2019
Phase: Phase 2
Study type: Interventional

The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).

NCT ID: NCT03808805 Recruiting - Clinical trials for Myeloproliferative Disorder

Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

APHYPAP
Start date: April 16, 2019
Phase: Phase 3
Study type: Interventional

Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.